The pathogensis and medical treatment of extrapyramidal disease.
D000328:Adult; D001264:Athetosis / Q000503:physiopathology; D001480:Basal Ganglia Diseases / Q000628:therapy*; D002421:Caudate Nucleus / Q000473:pathology; D002819:Chorea / Q000503:physiopathology; D003342:Corpus Striatum / Q000503:physiopathology; D004298:Dopamine / Q000502:physiology; D018492:Dopamine Antagonists; D004334:Drug Administration Schedule; D004421:Dystonia / Q000503:physiopathology; D005260:Female; D005971:Glutamates / Q000378:metabolism; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D006816:Huntington Disease / Q000378:metabolism; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000209:etiology*; D010300:Parkinson Disease / Q000188:drug therapy; D013981:Tic Disorders / Q000188:drug therapy; D005680:gamma-Aminobutyric Acid / Q000096:biosynthesis
D018492:Dopamine Antagonists; D005971:Glutamates; D007980:Levodopa; D005680:gamma-Aminobutyric Acid; D006220:Haloperidol; D004298:Dopamine